Clinical Trials

  • A white sign bears the word Sanofi at a road entrance to an office building.
    Image attribution tooltip
    JHVE Photo via Getty Images
    Image attribution tooltip

    Sanofi’s touted eczema drug hits study goal, but data fall short of expectations

    Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug class once viewed as particularly promising.

    By Kristin Jensen • Sept. 4, 2025
  • A 3D illustration of a ribosome as part of an biological cell constructing a messenger RNA molecule.
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip

    Wave shares sink on new study results for RNA editing drug

    Updated findings from Wave’s pioneering trial continued to show its RNA editing therapy is working as intended, but wasn’t as effective in testing as investors had hoped.  

    By • Sept. 3, 2025
  • Colorized scanning electron micrograph of a natural killer cell from a human donor. Explore the Trendline➔
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Cell therapy

    The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

    By BioPharma Dive staff
  • The exterior of Ionis Pharmaceuticals' headquarters in Carlsbad, California.
    Image attribution tooltip
    Courtesy of Ionis Pharmaceuticals
    Image attribution tooltip

    Ionis looks to expand use of lipid-lowering drug after trial hits goal

    Tryngolza, the first wholly owned drug Ionis has launched, helped people with high triglyceride levels that aren’t genetically driven.

    By • Sept. 2, 2025
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly says breast cancer drug extended survival in study

    Treatment with Verzenio helped people with a common type of early breast cancer liver longer than those given standard hormone therapy.

    By • Aug. 27, 2025
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly to submit obesity pill after hitting goal in third late-stage trial

    In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior testing.

    By • Aug. 26, 2025
  • A Regeneron sign in front of a building.
    Image attribution tooltip
    Courtesy of Regeneron Pharmaceuticals
    Image attribution tooltip

    RNA drug from Regeneron, Alnylam succeeds in rare autoimmune disease trial

    Cemdisiran helped control symptoms of generalized myasthenia gravis, but combination treatment with a Regeneron antibody didn't appear as effective.

    By • Updated Aug. 26, 2025
  • An illustration of glucose-dependent insulinotropic peptide.
    Image attribution tooltip
    Alioui Mohammed Elamine via Getty Images
    Image attribution tooltip
    Obesity drugs

    Viking shares sink as obesity pill misses expectations in key study

    The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations among people receiving Viking’s drug. 

    By • Aug. 19, 2025
  • A gloved hand holds a cluster of psilocybin mushrooms growing from a block of mycelium, illuminated by indoor lab lighting.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Reunion’s psychedelic drug headed to late-stage testing

    The drug, which functions similar to psilocybin, scored positive enough results in a mid-stage study that Reunion is now setting up a larger experiment to hopefully secure approval in postpartum depression.

    By • Aug. 18, 2025
  • An illustration of B cells producing antibodies
    Image attribution tooltip
    Love Employee via Getty Images
    Image attribution tooltip

    Vor says drug licensed from RemeGen succeeded in Sjögren’s study

    While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune condition.

    By • Aug. 13, 2025
  • A stylized illustration of the human urinary system with the bladder highlighted.
    Image attribution tooltip
    magicmine via Getty Images
    Image attribution tooltip

    Pfizer looks to expand ADC use after positive bladder cancer data

    Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify for chemotherapy.

    By • Aug. 12, 2025
  • An illustration of immune cells attacking a tumor.
    Image attribution tooltip
    Meletios Verras via Getty Images
    Image attribution tooltip

    IO Biotech sees path forward for skin cancer vaccine despite study setback

    A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe it still could win U.S. approval.

    By • Aug. 11, 2025
  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Sedat Suna via Getty Images
    Image attribution tooltip

    Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease

    The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a multibillion-dollar deal that hadn’t yet paid dividends.

    By • Aug. 11, 2025
  • Eli Lilly company logo outside its Indiana headquarters
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly shares fall as obesity pill misses expectations in key trial

    While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts anticipated, leading to a selloff in shares that erased about $100 billion in market value. 

    By • Aug. 7, 2025
  • A sign spelling Vertex hangs over an office building entrance.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip
    Pain drugs

    Vertex plan to build on pain drug breakthrough hits hurdles

    The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain would take more testing. A successor medicine, meanwhile, fell short in Phase 2.

    By • Aug. 5, 2025
  • An illustration of stock market quotes.
    Image attribution tooltip
    Алексей Белозерский via Getty Images
    Image attribution tooltip

    A brain biotech slumps even with ‘best case’ seizure data

    Positive results from a mid-stage study apparently weren’t enough to raise investor confidence in Praxis Precision Medicines and its experimental drug for epilepsy.

    By • Aug. 4, 2025
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly’s Mounjaro protects heart health in large diabetic study

    The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.

    By • July 31, 2025
  • A micrograph of estrogen receptor staining in a breast cancer tumor sample.
    Image attribution tooltip
    Douglas Olivares via Getty Images
    Image attribution tooltip

    Celcuity shares triple on late-stage results for breast cancer therapy

    Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to soon file for approval.

    By • July 28, 2025
  • An illustration of a brain disintegrating
    Image attribution tooltip
    Eoneren via Getty Images
    Image attribution tooltip

    Atai backs away from schizophrenia drug after trial failure

    The company plans to direct resources away from a drug developed by subsidiary Recognify Life Sciences and toward Atai’s wholly owned, psychedelics-focused pipeline.

    By • July 28, 2025
  • This image depicts the podcast series cover image for Pearson's BioPharma Dive series, "The Progress Profile: Alzheimer’s Research in Focus"
    Image attribution tooltip
    William Walker/BioPharma Dive
    Image attribution tooltip
    Sponsored by Pearson

    [Podcast] The Progress Profile: Alzheimer’s Research in Focus

    Discover the latest breakthroughs in Alzheimer's research, diagnosis, and prevention in this expert-led podcast series.

    By BioPharma Dive's studioID • July 24, 2025
  • A grey exterior sign with Alkermes' written on it sits in a bed of flowers outside a glass office building.
    Image attribution tooltip
    Permission granted by Karissa Waddick
    Image attribution tooltip

    Alkermes narcolepsy drug headed for late-stage testing

    Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts have guessed it could ultimately generate billions in sales.

    By • July 21, 2025
  • A sign reads "AstraZeneca" with the company logo on an all-glass-grided building facade.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    AstraZeneca rare disease drug fails key trial tests

    Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

    By • July 16, 2025
  • An illustration of glucose-dependent insulinotropic peptide.
    Image attribution tooltip
    Alioui Mohammed Elamine via Getty Images
    Image attribution tooltip
    Obesity drugs

    Hengrui, Kailera say dual-acting obesity shot succeeds in China study

    The results position Hengrui to seek approval of the Zepbound-like drug in China, and Kailera, a well-funded startup, to begin global late-stage testing.

    By • July 15, 2025
  • Close-up of a building with a purple and yellow AstraZeneca sign on the exterior.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    AstraZeneca blood pressure drug succeeds in late-stage trial

    Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose hypertension is either uncontrolled by or resistant to existing medicines.

    By • July 14, 2025
  • A sign with the logo for the Takeda pharmaceutical company.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Brain drug revival

    Takeda to seek approval of new kind of narcolepsy drug after study data

    Positive late-stage study results position the company to file for clearance of what could be the first narcolepsy drug that targets orexin proteins. 

    By • July 14, 2025
  • Laboratory technicians analyzing specimens
    Image attribution tooltip

    Adobe Stock / PaeGAG  

    Image attribution tooltip
    Sponsored by West Monroe

    From data to decisions: How pharma can move faster without sacrificing trust

    Pharma's speed advantage depends on trust. Is your data foundation strong enough?

    By Pankit Bhalodia, Partner at West Monroe Life Sciences • July 14, 2025